AzTrials
AzTrials

ObesityPhase 3SYNCHRONIZE™-2NCT06066528

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

A Phase 3 study testing Survodutide in people with Obesity and Diabetes Mellitus, Type 2, run by Boehringer Ingelheim at 143 sites in 19 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Obesity, Diabetes Mellitus, Type 2
What is being tested?
Survodutide
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
755 participants
Where
143 sitesin 19 countries
Study dates
27 Nov 2023to 1 Apr 2026
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female, age ≥18 years at the time of signing informed consent, and at least the legal age of consent in countries where it is >18 years.
  • Body mass index (BMI) ≥27 kg/m^2 at screening.
  • Diagnosed with Type 2 diabetes mellitus (T2DM) (defined as Glycosylated haemoglobin A1c (HbA1c) ≥6.5% [≥48 mmol/mol]) at least 180 days prior to screening.
  • HbA1c ≥6.5% (≥48 mmol/mol) and <10% (<86 mmol/mol) as measured by the central laboratory at screening.
  • Currently treated for T2DM with either diet and exercise alone or stable treatment (for at least 3 months prior to screening) per treatment guidelines.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight Further inclusion criteria apply.

Who cannot join

  • Body weight change (self-reported) of >5% within 3 months before screening.
  • Treatment with any medication for the indication obesity within 3 months before screening.
  • Treatment with any medication for indication of T2DM other than stated in the inclusion criteria and glucagon-like peptide-1 receptor (GLP-1R)-based agonists) and dipeptidyl peptidase 4 inhibitor [DPP-4il).
  • Known clinically significant gastric emptying abnormality (e.g., severe diabetic gastroparesis or gastric outlet obstruction).
  • History of either chronic or acute pancreatitis or elevation of serum lipase or amylase >2x upper limit of normal (ULN)) as measured by the central laboratory at screening.
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
  • Further exclusion criteria apply.

Trial locations and contacts

143 sites in 19 countries.

143 sites in 19 countries

United States34 sites

  • Pinnacle Research Group, LLC

    Anniston, Alabama, 36207

  • Emory University

    Atlanta, Georgia, 30303

  • Walgreens Clinical Trials-Atlantic City-69647

    Atlantic City, New Jersey, 08401

  • Texas Diabetes and Endocrinology

    Austin, Texas, 78731

  • Velocity Clinical Research - Binghamton

    Binghamton, New York, 13905

  • StudyMetrix Research, LLC

    City of Saint Peters, Missouri, 63303

  • Alliance for Multispecialty Research, LLC - Doral

    Doral, Florida, 33172

  • University of Florida

    Gainesville, Florida, 32610

  • Physicians East, PA

    Greenville, North Carolina, 27834

  • East-West Medical Research

    Honolulu, Hawaii, 96814

  • Juno Research, LLC

    Houston, Texas, 77040

  • East Coast Institute for Research, LLC - Jacksonville

    Jacksonville, Florida, 32216

  • AMR Lexington

    Lexington, Kentucky, 40509

  • L-MARC Research Center

    Louisville, Kentucky, 40213

  • Manassas Clinical Research Center

    Manassas, Virginia, 20110

  • Solaris Clinical Research

    Meridian, Idaho, 83646

  • New Horizon Research Center-Miami-69732

    Miami, Florida, 33165

  • Lucas Research, Inc.

    Morehead City, North Carolina, 28557

  • Trial Management Associates

    Myrtle Beach, South Carolina, 29572

  • West Orange Endocrinology

    Ocoee, Florida, 34761

  • EmVenio Research-Oklahoma City-70053

    Oklahoma City, Oklahoma, 73139

  • Walgreens - Perth Amboy - Site 4544

    Perth Amboy, New Jersey, 08861

  • EmVenio Research-Atlanta-69582

    Phoenix, Arizona, 85032

  • Rainier Clinical Research Center

    Renton, Washington, 98057

  • Diabetes & Glandular Disease Clinic, P.A.

    San Antonio, Texas, 78229

  • Consano Clinical Research

    Shavano Park, Texas, 78231

  • Velocity Clinical Research-Sioux City-69728

    Sioux City, Iowa, 51106

  • Evanston Premier Healthcare Research LLC

    Skokie, Illinois, 60077

  • Encompass Clinical Research, Spring Valley

    Spring Valley, California, 91978

  • Premier Research, Inc.

    Trenton, New Jersey, 08611

  • Velocity Clinical Research-Valparaiso-68883

    Valparaiso, Indiana, 46383

  • Diablo Clinical Research

    Walnut Creek, California, 94598

  • Southgate Medical Group/ Southgate Medical Park

    West Seneca, New York, 14224

  • Accellacare-Wilmington-67123

    Wilmington, North Carolina, 28401

Other trials in United States

China20 sites

  • Peking University People's Hospital

    Beijing, 100044

  • Beijing Pinggu Hospital

    Beijing, 101200

  • The First Hospital of Jilin University

    Changchun, 130021

  • Changzhou Second People's Hospital

    Changzhou, 213004

  • Guangdong Provincial People's Hospital

    Guangzhou, 510080

  • Forth Clinical Hospital of Harbin Medical University

    Harbin, 150599

  • Huzhou Central Hospital

    Huzhou, 313000

  • Center Hospital of Jinan

    Jinan, 250013

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, 471000

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, 210011

  • Pingxiang People's Hospital

    Pingxiang, 337000

  • Shanghai Municipal Hospital of Traditional Chinese Medicine

    Shanghai, 200071

  • Shanghai Fifth People's Hospital affiliated to Fudan University

    Shanghai, 200240

  • Siping Central People's Hospital

    Siping, 136000

  • Suzhou Municipal Hospital

    Suzhou, 215002

  • Tianjin Medical University General Hospital

    Tianjin, 30052

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, 430022

  • The First Affiliated Hospital of Xi'an Medical University

    Xi'an, 710077

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, 100029

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, 212013

Other trials in China

Canada11 sites

  • Aggarwal and Associates Ltd.

    Brampton, Ontario, L6T 0G1

  • Centricity Research (Calgary)

    Calgary, Alberta, T2H 2G4

  • The Wharton Medical Clinic Clinical Trials Inc.

    Hamilton, Ontario, L8L 5G8

  • Milestone Research Inc.

    London, Ontario, N5W 6A2

  • Recherche GCP Research

    Montreal, Quebec, H1Y 3H5

  • Power Clinical Research

    Montreal, Quebec, H3M 1L3

  • James Cha, MD

    Oshawa, Ontario, L1J 2K1

  • Stouffville Medical Research Institute Inc.

    Stouffville, Ontario, L4A 1H2

  • Albion Finch Medical Centre

    Toronto, Ontario, M9V 4B4

  • Dr. James Lai

    Vancouver, British Columbia, V5Z 4E1

  • Sameh Fikry Medicine Professional Corporation

    Waterloo, Ontario, N2J 1C4

Other trials in Canada

South Korea9 sites

  • The Catholic University of Korea, Bucheon St.Mary's Hospital

    Bucheon-si, 14647

  • Kyungpook National University Hospital

    Daegu, 41944

  • Dongguk University Ilsan Hospital

    Goyang, 10326

  • Gachon University Gil Medical Center

    Incheon, 21565

  • Seoul National University Bundang Hospital

    Seongnam, 13620

  • Seoul National University Hospital

    Seoul, 03080

  • Severance Hospital

    Seoul, 03722

  • The Catholic University of Korea, Yeouido St.Mary's Hospital

    Seoul, 07345

  • Ajou University Hospital

    Suwon, 16499

Other trials in South Korea

Australia8 sites

  • Monash University

    Box Hill, Victoria, 3128

  • Austin Health

    Heidelberg, Victoria, 3084

  • Nepean Hospital

    Kingswood, New South Wales, 2747

  • Baker Heart and Diabetes Institute

    Melbourne, Victoria, 3004

  • Hunter Diabetes Centre

    Merewether, New South Wales, 2291

  • CORE Research Group

    Milton, Queensland, 4064

  • Keogh Institute for Medical Research

    Nedlands, Western Australia, 6009

  • Griffith Health

    Southport, Queensland, 4125

Other trials in Australia

Spain7 sites

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, 15006

  • Hospital Vithas Sevilla

    Castilleja de la Cuesta, 41950

  • Hospital Arnau de Vilanova

    Lleida, 25198

  • Hospital General Universitario Gregorio Marañón

    Madrid, 28009

  • Clínica Universidad de Navarra - Madrid

    Madrid, 28027

  • Clínica Universidad de Navarra

    Pamplona, 31008

  • Hospital de Canarias

    San Cristóbal de La Laguna, 38320

Other trials in Spain

Germany6 sites

  • InnoDiab Forschung GmbH

    Essen, 45136

  • MVZ im Altstadt-Caree Fulda GmbH

    Fulda, 36037

  • Diabetes Zentrum Hamburg West

    Hamburg, 22607

  • Institut für Diabetesforschung Münster GmbH

    Münster, 48145

  • R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH

    Oldenburg in Holstein, 23758

  • Forschungszentrum Ruhr, KliFo Center GmbH

    Witten, 58455

Other trials in Germany

Japan6 sites

  • Fukuhama Chuo Clinic

    Fukuoka, Fukuoka, 810-0066

  • Itabashi Diabetic medicine and Dermatology Clinic

    Ibaraki, Koga, 306-0232

  • Nagase Clinic

    Ibaraki, Ushiku, 300-1207

  • Soka Sugiura Naika Clinic

    Saitama, Soka, 340-0034

  • Oyama East Clinic

    Tochigi, Oyama, 323-0022

  • Hachioji Diabetes Clinic

    Tokyo, Hachioji, 192-0083

Other trials in Japan

Czechia5 sites

  • Edumed s.r.o

    Broumov, 55001

  • NZZ Agentura Science Pro s.r.o., Olomouc

    Olomouc, 772 00

  • Dieko, s.r.o.

    Pilsen, 301 00

  • Polyclinic Michnova Ltd.

    Prague, 149 00

  • Private Practice - Dr. Barbora Diepoltova

    Prague, 190 14

Other trials in Czechia

Hungary5 sites

  • DRC Drug Research Ltd-Balatonfured-59734

    Balatonfüred, 8230

  • Belinus Bt

    Debrecen, 4025

  • CRU Hungary Ltd.

    Kistarcsa, 2143

  • Arina Trial Research kft.

    Orosháza, 5900

  • University of Szeged

    Szeged, 6725

Other trials in Hungary

New Zealand5 sites

  • P3 Research Dunedin

    Dunedin, 9016

  • Southern Clinical Trials Tasman

    Nelson, 7011

  • P3 Research-Newtown Wellington NZ-33770

    Newtown Wellington NZ, 6021

  • Optimal Clinical Trials North

    Rosedale, Auckland, 0632

  • P3 Research-Tauranga-34833

    Tauranga, 3110

Other trials in New Zealand

Poland5 sites

  • PI HOUSE Sp. z o.o., Gdansk

    Gdansk, 80546

  • ETG Lublin

    Lublin, 20-412

  • Velocity Nova Sp z o.o.

    Puławy, 24-100

  • ETG Siedlce

    Siedlce, 08-110

  • METABOLICA Sp.zo.o. NZOZ METABOLICA Osrodek badan klinicznych

    Tarnów, 33-100

Other trials in Poland

Sweden5 sites

  • Ladulaas Kliniska Studier

    Borås, 506 30

  • Forskningsenheten Carlanderska

    Gothenburg, 40545

  • Pharmasite Malmo

    Malmö, 211 52

  • Medicinmottagning 5/Överviktsenheten

    Örebro, 70362

  • Sabbatsbergs sjukhus

    Stockholm, 113 61

Other trials in Sweden

United Kingdom5 sites

  • Waterloo Medical Centre

    Blackpool, FY4 3AD

  • Bradford on Avon Health Centre

    Bradford on Avon, BA15 1DQ

  • Mounts Bay Medical Limited

    Hayle, TR27 5DT

  • Clifton Medical Centre, Rotherham

    Rotherham, S65 1DA

  • Trowbridge Health Centre

    Trowbridge, BA14 8LW

Other trials in United Kingdom

Belgium3 sites

  • ASZ - Campus Aalst

    Aalst, 9300

  • UZ Leuven

    Leuven, 3000

  • AZ Delta

    Roeselare, 8800

Other trials in Belgium

Finland3 sites

  • HUS, Lihavuustutkimusyksikkö Biomedicum Helsinki

    Helsinki, 00290

  • Itä-Suomen yliopisto/Health Step Finland Oy

    Kuopio, 70600

  • CRST - Clinical Research Services Turku

    Turku, 20520

Other trials in Finland

Greece3 sites

  • Athens Medical Center

    Athens, 15125

  • Thermi Clinic

    Thermi, 57001

  • Nexthealth S.A

    Thessaloniki, 54645

Other trials in Greece

Netherlands2 sites

  • PT & R

    Born, 6121 XK

  • Universitair Medisch Centrum Groningen

    Groningen, 9713 EZ

Other trials in Netherlands

Denmark1 site

  • Sanos Clinic Gandrup (SMO)

    Gandrup, 9362

Other trials in Denmark

About this study

Official title: A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate.

The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight.

Read more

Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.

Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff.

The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.

Being tested
Survodutide, Placebo
Medical subject headings
Obesity, Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SurvodutideCombination product

    Also called BI 456906

    once weekly subcutaneous injection, pre-filled syringe

  • PlaceboCombination product

    once weekly subcutaneous injection, pre-filled syringe

Study groups in NCT06066528
Study groupRoleWhat they receive
Survodutide 3.6 mgExperimentalNot described
Receives: Combination Product: Survodutide
Survodutide 6.0 mgExperimentalNot described
Receives: Combination Product: Survodutide
PlaceboPlacebo comparatorNot described
Receives: Combination Product: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage change in body weight from baseline to Week 76

    Measured: Baseline and at Week 76

  2. Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76

    Measured: Baseline and at Week 76

Secondary outcomes (22)

  1. Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76

    Measured: Baseline and at Week 76

  2. Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76

    Measured: Baseline and at Week 76

  3. Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76

    Measured: Baseline and at Week 76

  4. Absolute change from baseline to Week 76 in body weight (kg)

    Measured: Baseline and at Week 76

  5. Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)

    Measured: Baseline and at Week 76

  6. Absolute change from baseline to Week 76 in waist circumference (cm)

    Measured: Baseline and at Week 76

  7. Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)

    Measured: Baseline and at Week 76

  8. Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of Eating Behaviour patient reported outcome (PRO)

    "Capacity to Resist" domain score of the Eating Behaviour PRO is ranging between 0 and 24 and a higher score indicates a lower capacity to resist.

    Measured: Baseline and at Week 76

  9. Key secondary endpoint: Absolute change from baseline to Week 76 in Eating Behaviour PRO total score

    Eating Behaviour PRO total score is ranging between 0 and 48 and a higher score indicates a worse eating behaviour (greater desire to eat and/or lower capacity to resist).

    Measured: Baseline and at Week 76

  10. Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)

    Measured: Baseline and at Week 76

  11. Absolute change from baseline to Week 76 in HbA1c (mmol/mol)

    Measured: Baseline and at Week 76

  12. Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)

    Measured: Baseline and at Week 76

  13. Absolute change from baseline to Week 76 in fasting plasma glucose (FPG) (mg/dL)

    Measured: Baseline and at Week 76

  14. Absolute change from baseline to Week 76 in fasting plasma insulin (FPI) (mIU/L)

    Measured: Baseline and at Week 76

  15. Absolute change from baseline to Week 76 in total cholesterol (mg/dL)

    Measured: Baseline and at Week 76

  16. Absolute change from baseline to Week 76 in high density lipoprotein (HDL) cholesterol (mg/dL)

    Measured: Baseline and at Week 76

  17. Absolute change from baseline to Week 76 in low density lipoprotein (LDL) cholesterol (mg/dL)

    Measured: Baseline and at Week 76

  18. Absolute change from baseline to Week 76 in very-low-density lipoprotein (VLDL) cholesterol (mg/dL)

    Measured: Baseline and at Week 76

  19. Absolute change from baseline to Week 76 in triglycerides (mg/dL)

    Measured: Baseline and at Week 76

  20. Absolute change from baseline to Week 76 in free fatty acids (mg/dL)

    Measured: Baseline and at Week 76

  21. Absolute change from baseline to Week 76 in alanine aminotransferase (ALT) (U/L)

    Measured: Baseline and at Week 76

  22. Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L)

    Measured: Baseline and at Week 76

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2023
  2. Study start27 Nov 2023
  3. Primary completion12 Dec 2025
  4. Study completion1 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
755 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06066528
Sponsor's protocol ID
1404-0041
Other IDs
2022-502531-18-00, U1111-1289-0247
Acronym
SYNCHRONIZE™-2
Status last verified
Aug 2026
First submitted
27 Sep 2023
Last updated
6 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Publications

  • Wharton S, le Roux CW, Startseva E, Kloer IM, Alhussein A, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdanski P, Butt JH, Ekinci EI, Jastreboff AM, Ji L, Schou M, Tinahones FJ, Kokkinos AD, Merkely B, Ogawa W, Pedersen SD, Pietilainen KH, Quinn D, Sattar N, Seufert J, Stenlof K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM; SYNCHRONIZE-2 Investigators. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med. 2026 Oct 1. doi: 10.1056/NEJMoa2607219. Online ahead of print.

    PubMed 42820639

  • Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM. Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb;28(2):1490-1498. doi: 10.1111/dom.70263. Epub 2025 Nov 11.

    PubMed 41216778

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Survodutide in people with Obesity and Diabetes Mellitus, Type 2, run by Boehringer Ingelheim at 143 sites in 19 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 143 sites in United States, China, Canada, South Korea, Australia and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage change in body weight from baseline to Week 76 (time frame: Baseline and at Week 76). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06066528, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
SYNCHRONIZE™-2 Clinical Trial NCT06066528 | AzTrials